S100A4, Human, mAb 5A3
The monoclonal antibody clone 5A3 recognizes S100A4. S100A4 is a member of the S100 family. To date, the family consists of 22 members. S100 proteins are low molecular weight calcium binding proteins. The proteins consist of 2 calcium binding EF-hands located on the termini flanked by hydrophobic hinge regions. Calcium ions acts as a global second messenger involved in the regulation of many aspects of cell function. S100 proteins are involved in sensing and transforming calcium signals to downstream cellular responses. S100 proteins are located in the cytoplasm and/or nucleus of a wide range of cell types and involved in the regulation of cellular processes such as cell cycle progression and differentiation and inflammatory responses. Several S100 members have been found to act as cytokines in inflammation, particularly in autoimmune skin conditions such as psoriasis. S100A4 may function in motility, invasion, and tubulin polymerization. Chromosomal rearrangements and altered S100A4 gene expression have been implicated in tumor metastasis. Studies have shown that S100A4 is involved tumor progression and metastasis in various malignant tumors. Detection of S100A4 expression becomes a promising candidate biomarker in cancer early diagnosis and prediction of cancer metastasis. Therefore S100A4 may have high therapeutic value.
FS: Antibody clone 5A3 can be used as blocking antibody.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA